A multicentre, randomized, split face and/or neck comparison of 308-nm excimer laser and 0·1% tacrolimus ointment for stable vitiligo plus intramuscular slow-releasing betamethasone for active vitiligo

Br J Dermatol. 2019 Jul;181(1):210-211. doi: 10.1111/bjd.17630. Epub 2019 Mar 21.

Authors

Y Wu¹, Y Sun¹, L Qiu¹, H Wang¹, Y Zhang¹, K Chen², H Li³, H Gu², J Zhang³, X-H Gao¹

Affiliations

¹ Department of Dermatology, The First Hospital of China Medical University, Shenyang, China.
² Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, China.
³ Department of Dermatology, The People's Hospital of Peking University, Beijing, China.

PMID: 30644997
DOI: 10.1111/bjd.17630

No abstract available

Publication types

Comparative Study
Letter
Multicenter Study
Randomized Controlled Trial

MeSH terms

Administration, Cutaneous
Adult
Betamethasone / administration & dosage*
Betamethasone / adverse effects
Combined Modality Therapy / methods
Face
Female
Humans
Injections, Intramuscular
Lasers, Excimer / therapeutic use*
Low-Level Light Therapy / adverse effects
Low-Level Light Therapy / instrumentation*
Low-Level Light Therapy / methods
Male
Middle Aged
Neck
Skin Pigmentation / drug effects
Skin Pigmentation / radiation effects
Tacrolimus / administration & dosage*
Tacrolimus / adverse effects
Treatment Outcome
Vitiligo / therapy*

Substances

Betamethasone
Tacrolimus